← The Wire
ALNYNasdaq
ALNYLAM PHARMACEUTICALS, INC.
Pharmaceutical Preparations · CIK 1178670
Developing novel therapeutics based on RNA interference to silence genes causing disease
red 8-K · 90d
$37.76B
Market cap
$293.52
Last close
+0.7%
1D
+2.5%
5D
1.4M
Volume
Price · last 39 sessions-1.5%
May 4L $278.09 · H $305.06Jun 29
227
Total filings
May 27, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 27, 202610-Q10-QApr 30, 20268-KResults of OperationsApr 30, 2026DEFA14ADEFA14AApr 6, 2026DEF 14ADEF 14AApr 6, 20268-KExecutive ChangeMar 4, 202610-K10-KFeb 12, 20268-KResults of OperationsFeb 12, 20268-KResults of OperationsJan 12, 20268-KCompany UpdateDec 11, 20258-KExecutive ChangeDec 3, 202510-Q10-QOct 30, 20258-KResults of OperationsOct 30, 20258-KMaterial Agreement · New Debt / ObligationOct 3, 20258-KMaterial Agreement · New Debt / ObligationSep 12, 20258-KCompany UpdateSep 10, 202510-Q10-QJul 31, 20258-KResults of OperationsJul 31, 20258-KExecutive ChangeJun 18, 20258-KBylaw Amendment · Shareholder VoteMay 13, 202510-Q10-QMay 1, 20258-KCompany UpdateMay 1, 2025DEFA14ADEFA14AApr 4, 2025DEFA14ADEFA14AMar 24, 2025DEF 14ADEF 14AMar 24, 20258-KCompany UpdateMar 21, 20258-KExecutive ChangeMar 5, 202510-K10-KFeb 13, 20258-KCompany UpdateFeb 13, 20258-KResults of OperationsJan 13, 202510-Q10-QOct 31, 20248-KCompany UpdateOct 31, 202410-Q10-QAug 1, 20248-KCompany UpdateAug 1, 20248-KShareholder VoteMay 20, 202410-Q10-QMay 2, 20248-KCompany UpdateMay 2, 2024DEFA14ADEFA14AApr 1, 2024DEF 14ADEF 14AApr 1, 20248-KExecutive ChangeMar 4, 202410-K10-KFeb 15, 20248-KResults of OperationsFeb 15, 20248-KExecutive ChangeJan 19, 20248-KResults of OperationsJan 8, 202410-Q10-QNov 2, 20238-KResults of OperationsNov 2, 20238-KCompany UpdateOct 10, 20238-KExecutive ChangeSep 28, 202310-Q10-QAug 3, 20238-KExecutive Change · Results of OperationsAug 3, 20238-KMaterial Agreement · Reg FD DisclosureJul 26, 20238-KCompany UpdateJun 30, 20238-KShareholder VoteMay 23, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEFA14ADEFA14AApr 3, 2023DEF 14ADEF 14AApr 3, 20238-KExecutive ChangeMar 8, 202310-K10-KFeb 23, 20238-KResults of OperationsFeb 23, 20238-KResults of OperationsJan 9, 20238-KExecutive Change · Company UpdateJan 6, 202310-Q10-QOct 27, 20228-KResults of OperationsOct 27, 20228-KMaterial Agreement · Agreement TerminatedSep 16, 20228-KCompany UpdateSep 13, 2022SC 13GSEC SCHEDULE 13GSep 9, 20228-KExecutive ChangeAug 24, 202210-Q10-QJul 28, 20228-KResults of OperationsJul 28, 20228-KCompany UpdateJun 14, 20228-KShareholder VoteMay 23, 202210-Q10-QApr 28, 20228-KResults of OperationsApr 28, 2022DEFA14ADEFA14AApr 5, 2022DEF 14ADEF 14AApr 5, 20228-KExecutive ChangeApr 5, 20228-KCompany UpdateApr 4, 20228-KCompany UpdateMar 17, 2022SC 13GSC 13GFeb 14, 2022
Insider Activity
In the 90 days to Mar 5, 2026: 5 sold $24.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 740 | $323.55 | $239K |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 654 | $322.33 | $211K |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 510 | $324.59 | $166K |
| Mar 5, 2026 | Garg PushkalEVP Chief R&D | Sell | 500 | $326.08 | $163K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 233 | $323.25 | $75K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 153 | $326.24 | $50K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 148 | $324.60 | $48K |
| Mar 5, 2026 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Sell | 124 | $321.81 | $40K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 973 | $323.84 | $315K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 818 | $323.84 | $265K |
| Mar 4, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sell | 767 | $323.84 | $248K |
| Mar 4, 2026 | Garg PushkalEVP Chief R&D | Sell | 767 | $323.84 | $248K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 444 | $323.01 | $143K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 374 | $323.01 | $121K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 368 | $321.82 | $118K |
| Mar 4, 2026 | Garg PushkalEVP Chief R&D | Sell | 350 | $323.01 | $113K |
| Mar 4, 2026 | Tanguler TolgaEVP, Chief Commercial Officer | Sell | 350 | $323.01 | $113K |
| Mar 4, 2026 | Greenstreet YvonneChief Executive Officer | Sell | 345 | $324.88 | $112K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 309 | $321.82 | $99K |
| Mar 4, 2026 | Poulton Jeffrey V.EVP, Chief Financial Officer | Sell | 291 | $324.88 | $95K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance